Firebrick Pharma Ltd (fre) Logo

Firebrick Pharma Ltd (FRE)

___:___ · Healthcare
ASX Delayed
Cboe Live

What is live streaming pricing?

Stock prices will auto-update without reloading the page. How it works:

  • Flashing prices signify an increase (green) or decrease (red) from previous price. Otherwise, price is unchanged.
  • Expect a short delay while pricing data initially loads.
  • Note, prices only update during market hours (10am-4:13pm AEST).

More about Cboe Live pricing.

OK, got it
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE

FRE ASX Chart

Snapshot

Firebrick Pharma Limited (FRE) is a pharmaceutical company founded in 2012 to develop and commercialise a nasal spray treatment for the common cold based around the potential of povidone-iodine as a broad-spectrum antimicrobial agent. The Company subsequently developed Nasodine� Nasal Spray (“Nasodine") and owns numerous granted and pending patents. Firebrick is currently undertaking two significant clinical trials: A Phase 2 trial of Nasodine in COVID-19 and a Phase 3 trial for Nasodine, to confirm its efficacy as a treatment for the common cold and support international approvals.

Share Price Activity (ASX)

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume
Volume (4w avg)
Turnover
Open
Day Range -
VWAP
Prev Close
Last Trade

Performance

1 Week
1 Month
2024 YTD
1 Year
vs Sector (1yr) -
vs ASX 200 (1yr) -80.77%

Size

Market Cap Question Mark Icon
Excludes mandatory escrowed shares and foreign shares.
ASX Rank 1,855 of 2,400
Sector Rank 179 of 223

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies ESE / HIQ / TRU
EPS -$0.04
DPS $0.00
Book Value Per Share $0.014

Broker Consensus

FRE is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.

Announcements

Price Sensitive only

Corporate Overview

Corporate Details

Head Office Creswick VIC 3363
Website www.firebrickpharma.com
Registry Automic Group
Auditor BDO Audit (WA) Pty Ltd
Date Listed 28 Jan 2022

Upcoming Calendar (Forecasted)

Date Event
27/08/2024 Report (Prelim)
27/08/2024 Report (Annual)

Former Company Names

  • Firebrick Pharma Ltd has no former company names.

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors

Management

Director Transactions

FRE directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
20/06/23 Stephen Goodall Issued 530,000 $0.150 $79,500 Placement
20/06/23 Stephen Goodall Transfer 30,326,472 $0.155 $4,700,603 Off-market transfer
20/06/23 Stephen Goodall Transfer 30,326,472 $0.155 $4,700,603 Off-market transfer
20/06/23 Peter Molloy Transfer 30,326,472 $0.155 $4,700,603 Off-market transfer
20/06/23 Peter Molloy Transfer 30,326,472 $0.155 $4,700,603 Off-market transfer
20/06/23 Peter Molloy Issued 530,000 $0.150 $79,500 Placement
24/11/22 Phyllis Gardner Issued 100,000 $0.173 $17,325 Director remuneration
24/11/22 Richard Treagus Issued 100,000 $0.173 $17,325 Director remuneration

Director Interests

The current holdings of FRE directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Phyllis Gardner 30/06/2023 600,000 N/A 100,000 N/A
Richard Treagus 30/06/2023 N/A N/A 100,000 N/A
Stephen Goodall 30/06/2023 N/A 30,856,472 N/A N/A
Peter Molloy 30/06/2023 N/A 30,856,472 N/A N/A

Shareholder Info

Top 20 Shareholders

Data supplied by Morningstar and accurate on Aug 10, 2023.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Aquarico Pty Ltd <P & C Molloy Family A/C> 30,326,472 17.21%
Biotech Design Pty Ltd 30,326,472 17.21%
Zero Nominees Pty Ltd 6,391,000 3.63%
BNP Paribas Noms Pty Ltd <DRP> 3,250,017 1.84%
BNP Paribas Nominees Pty Ltd HUB24 Custodial Serv Ltd <DRP A/C> 3,148,844 1.79%
Mr Ivan Kaufman 2,550,000 1.45%
Kashflow 18 LLC 2,103,713 1.19%
Dr Jonathan Bryden Dalitz & Mrs Michelle Anne Dalitz <Dalitz Super Fund A/C> 2,000,000 1.13%
Mr Richard Friedland 1,840,000 1.04%
Mr Paul Hartley Watts 1,700,000 0.96%
GZ Family Holdings Pty Ltd <GZ Family A/C> 1,700,000 0.96%
Ms Helen Frances Morgan 1,550,000 0.88%
BT Portfolio Services Limited <Warrell Holdings S/F A/C> 1,500,000 0.85%
Greensea Investments Pty Ltd 1,400,000 0.79%
Citicorp Nominees Pty Limited 1,344,328 0.76%
Mr Andrew John Mccormack 1,202,000 0.68%
Netwealth Investments Limited <Wrap Services A/C> 1,185,937 0.67%
Tubechangers Pty Ltd <King Family A/C> 1,100,000 0.62%
Greenford Pty Ltd <Kluger Super Fund A/C> 1,040,000 0.59%
Dr Simon Peter Tucker 1,000,000 0.57%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 779 1,978 657 768 163 4,345

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Note: If a substantial shareholder's stake drops below 5%, the "Shareholders Selling" field shows full ownership as sold and sets "New %" to zero, even if they continue to hold shares under the limit.

Name Last Notice Total Shares Shares Held (%)
Firebrick Pharma Limited 10/08/2023 62,732,537 37.15
Biotech Design Pty Ltd 10/08/2023 30,326,472 17.96
Aquarico Pty Ltd 10/08/2023 30,326,472 17.96

Shareholders Buying

12 month transaction history compiled from ASX announcements.

No buy transactions reported by Substantial Shareholders in the past 12 months.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2023 $0.155 30 June
2022 $0.265 30 June
FRE Historical Price Data (CSV)
Up to 20 years of EOD share price history

Important note:

All year-end and CSV data is "as traded on the day" and ignores corporate actions (e.g. share splits)

Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.